Clinical trials: Cardiovascular Complications
Non-healing Wound, Diabetic Foot Ulcer
Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers
The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with 510K FDA cleared, commercially available self-assembling peptide, AC5®Advanced Wound…
- Trial name
- NCT06028386
- Testing
- AC5® Advanced Wound System, Fibracol Plus Collagen Dressing
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Arch Therapeutics
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Foot Ulcer, Diabetic Foot
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
The purpose of this study is to evaluate the efficacy and safety of REGRANEX® Gel compared with placebo when applied for up to 52 consecutive weeks to recurring or non-healing ulcers of the ankle or foot related to diabetes.
- Conditions
- Foot Ulcer, Diabetic Foot, Skin Ulcer, Diabetic Neuropathies
- Trial name
- NCT00034788
- Testing
- Becaplermin
- Volunteers
- 84 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prostatic Neoplasms, Multiple Myeloma
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment.
- Conditions
- Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma
- Trial name
- NCT00050687
- Testing
- Gallium maltolate
- Where
- 5 sites in United States
- Sponsor
- Titan Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists
This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in…
- Trial name
- SPARK-CVD (NCT06589791)
- Testing
- No treatment given
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Novo Nordisk A/S
Chronic Ulcers, Diabetic Foot Ulcers (DFU)
Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic Wounds
The purpose of this observational case series is to assess the use of Corplex P as a resorbable particulate device used to cover, protect, and provide a moist wound environment when added to the standard of care treatment of…
- Conditions
- Chronic Ulcers, Diabetic Foot Ulcers (DFU), DFU, Ulcer
- Trial name
- NCT07414368
- Testing
- Corplex P is used to cover, protect, and provide a moist wound environment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- StimLabs
Diabetic Retinopathy
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
This study is open to adults with diabetic macular ischemia who have received laser treatment. The main purpose of this study is to find out whether people with diabetic macular ischemia can tolerate a medicine called BI 765128.
- Trial name
- PARTRIDGE (NCT04919499)
- Testing
- BI 765128
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Diabetic Foot Ulcer
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
This prospective, multi-center, randomized, controlled modified platform Trial compares Purified Native Type 1 Collagen Extracellular Matrix with Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care versus…
- Trial name
- PREPARE (NCT06618612)
- Testing
- Standard of Care, PuraPly AM, PuraPly XT
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Organogenesis
Heart Decompensation, Heart Failure, Congestive
Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients
The study is intended to verify the safety and assess the performance of up to 3-days treatment protocol with the RenaSense System in ADHF patients.
- Conditions
- Heart Decompensation, Heart Failure, Congestive, Renal Insufficiency
- Trial name
- NCT02324400
- Testing
- RenaSense Stimulation
- Where
- 3 sites in Israel
- Volunteers
- 36 people
- Sponsor
- Nephera Ltd.
Heart Failure, Cardiorenal Syndrome
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy.
- Conditions
- Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF
- Trial name
- DRAIN-HF (NCT05677100)
- Testing
- Aortix System
- Where
- 50 sites in United States, Hungary
- Volunteers
- 320 people
- Sponsor
- Procyrion
Diabetic Foot Ulcers
Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers
To determine if topical negative pressure therapy delivered by the V.A.C.® device is clinically efficacious and cost effective in the treatment of diabetic foot ulcers.
- Trial name
- NCT00432965
- Testing
- Moist Wound Therapy, VAC Therapy
- Where
- 25 sites in United States, Canada
- Volunteers
- 335 people
- Sponsor
- KCI USA, Inc
Aortic Valve Stenosis
A Study to Evaluate the Neuro-embolic Consequences of TAVR
A prospective, multi-center study to evaluate the neuro-embolic consequences of Transcatheter Aortic Valve Replacement (TAVR)
- Trial name
- NCT02073864
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Keystone Heart
Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Expanded Access Program for Selinexor
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma
- Trial name
- KEAP (NCT07215832)
- Testing
- selinexor
- Sponsor
- Karyopharm Therapeutics Inc
Diabetic Foot Ulcer, Venous Leg Ulcer
A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of hard-to-heal…
- Trial name
- NCT06453187
- Testing
- Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers, Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers, AmnioExcel Plus for Venous Leg Ulcers
- Where
- 13 sites in United States
- Volunteers
- 350 people
- Sponsor
- Integra LifeSciences Corporation
Diabetic Foot Ulcers (DFUs)
Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU
The goal of this clinical trial is to learn if drug Nu-3 works to treat mildly infected diabetic foot ulcers in adults with Type 1 or Type 2 diabetes at 3 different dose levels. It will also learn about the safety of drug Nu-3.
- Trial name
- NCT07565506
- Testing
- Antimicrobial agent
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Lakewood-Amedex Inc
Diabetic Foot Ulcers
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
The purpose of the study is to determine if DSC127 is effective in increasing incidence of complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the vehicle (gel without active ingredient) in…
- Trial name
- STRIDE 1 (NCT01830348)
- Testing
- DSC127
- Where
- 25 sites in United States
- Volunteers
- 266 people
- Sponsor
- Integra LifeSciences Corporation
Diabetic Foot Ulcer
Blue Light Photobiomodulation Therapy on Neuroischemic Patients
This is a pilot case/control clinical study on a group of outpatients with diabetic foot lesions aiming to verify the efficacy and safety of the Blue light photobiomodulation therapy with EmoLED medical device, in addition to…
- Trial name
- HERMES (NCT04831606)
- Testing
- debridement, Offloading, Advanced dressing
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Emoled
Diabetic Foot Ulcer
A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers
This prospective case series is to gain additional clinical experience in the treatment of diabetic foot ulcers, by documenting and relating patient history (including baseline wound characteristics) and clinical outcomes…
- Trial name
- NCT02799121
- Testing
- ReGenerCell™ Autologous Cell Harvesting Device
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Avita Medical
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.